loading page

Successful first-line treatment of hemophagocytic lymphohistiocytosis with ruxolitinib in a pediatric patient with trisomy 21
  • Katelyn N. Swizer,
  • Morgan Beebe,
  • Miriam B. Garcia
Katelyn N. Swizer
C S Mott Children's Hospital Division of General Pediatrics
Author Profile
Morgan Beebe
Nationwide Children's Hospital
Author Profile
Miriam B. Garcia
The University of Texas MD Anderson Cancer Center Children's Cancer Hospital

Corresponding Author:[email protected]

Author Profile

Abstract

Hemophagocytic lymphohistiocytosis (HLH) is an uncommon immunologic disorder associated with high rates of morbidity and mortality characterized by systemic inflammation and multiorgan dysfunction. The standard of care for primary treatment of HLH is chemotherapy (i.e. etoposide), but consideration of alternative therapies is warranted to support treatment goals for critically ill pediatric patients. We present the case of a 7-year-old male with trisomy 21, acute multiorgan failure secondary to infection, and subsequent HLH who was successfully treated with ruxolitinib. This represents the first use of ruxolitinib as a first-line agent for secondary HLH in a critically ill child with trisomy 21.
19 Dec 2022Submitted to Pediatric Blood & Cancer
19 Dec 2022Submission Checks Completed
19 Dec 2022Assigned to Editor
19 Dec 2022Review(s) Completed, Editorial Evaluation Pending
19 Dec 2022Editorial Decision: Revise Minor
02 Jan 2023Submission Checks Completed
02 Jan 2023Assigned to Editor
02 Jan 20231st Revision Received
02 Jan 2023Review(s) Completed, Editorial Evaluation Pending
03 Jan 2023Reviewer(s) Assigned
09 Jan 2023Editorial Decision: Revise Minor
18 Jan 2023Submission Checks Completed
18 Jan 2023Assigned to Editor
18 Jan 20232nd Revision Received
18 Jan 2023Review(s) Completed, Editorial Evaluation Pending
18 Jan 2023Editorial Decision: Accept